Natixis Advisors, L.P. Coherus Bio Sciences, Inc. Transaction History

Natixis Advisors, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$5.86 - $13.23 $114,035 - $257,455	-19,460 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$10.92 - $16.41 $29,342 - $44,093	2,687 Added 16.02%	19,460 $251,000
Q4 2021 Feb 08, 2022	BUY	$15.81 - $18.99 $30,560 - $36,707	1,933 Added 13.03%	16,773 $268,000
Q3 2021 Nov 15, 2021	BUY	$12.68 - $17.79 $188,171 - $264,003	14,840 New	14,840 $238,000
Q1 2021 May 05, 2021	SELL	$14.42 - $21.39 $2.36 Million - $3.51 Million	-163,934 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$16.56 - $18.94 $2.71 Million - $3.1 Million	163,934 New	163,934 $2.85 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $106M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Natixis Advisors, L.P. with notifications on news.